Holen Sie sich die Stockscreener-App
1.645
0.30%
-0.005
Handel nachbörslich:
1.64
-0.005
-0.30%
Schlusskurs vom Vortag:
$1.65
Offen:
$1.69
24-Stunden-Volumen:
64,325
Relative Volume:
0.71
Marktkapitalisierung:
$5.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.66M
KGV:
-0.0862
EPS:
-19.0729
Netto-Cashflow:
$-49.98M
1W Leistung:
-18.56%
1M Leistung:
-76.57%
6M Leistung:
-87.12%
1J Leistung:
+257.61%
1-Tages-Spanne:
$1.55
$1.7899
1-Wochen-Bereich:
$1.55
$2.11
52-Wochen-Spanne:
$0.39
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Firmenname
Nextcure Inc
Sektor
Branche
Telefon
240-399-4900
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
1.645 | 5.96M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-03-05 | Hochstufung | Truist | Hold → Buy |
| 2021-01-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Herabstufung | SunTrust | Buy → Hold |
| 2020-06-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-03-24 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-02 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-05 | Eingeleitet | Needham | Buy |
| 2019-11-26 | Eingeleitet | BTIG Research | Buy |
| 2019-07-09 | Eingeleitet | BofA/Merrill | Buy |
| 2019-06-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
NextCure, Inc. Actuals & Estimates (NASDAQ:NXTC) - TradingView
NextCure, Inc. Actuals & Estimates (FWB:2US0) - TradingView
NextCure Inc (NXTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NXTC Forecast — Price Target — Prediction for 2027 - TradingView
NextCure, Inc. Actuals & Estimates (BOATS:NXTC) - TradingView
2US0 Forecast — Price Target — Prediction for 2027 - TradingView
What's going on with NextCure stock Wednesday? - MSN
NextCure Shareholders Approve Expanded Omnibus Incentive Plan - TipRanks
NextCure (NASDAQ: NXTC) shareholders back amended 2019 incentive plan and director slate - Stock Titan
NextCure Inc (NXTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NextCure (NXTC) director receives 2,340 options at $2.02 strike - Stock Titan
Director at NextCure (NASDAQ: NXTC) granted 2,340 stock options - Stock Titan
NextCure (NXTC) director awarded 2,340 options at $2.02 exercise price - Stock Titan
NextCure (NXTC) director receives grant of 2,340 stock options at $2.02 - Stock Titan
NextCure (NXTC) director awarded options for 2,340 shares at $2.02 - Stock Titan
NextCure (NASDAQ: NXTC) director receives stock options grant for 3,510 shares - Stock Titan
NextCure Stocklong-term oncology model under scrutiny - Ad-hoc-news.de
NextCure Inc (NXTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NextCure (NXTC) AGM 2026 Summary - Quartr
NextCure Inc (NXTC) Institutional Confidence - TradingKey
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NextCure Inc (NXTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXTC | NextCure, Inc. Common Stock Insider Trading - Quiver Quantitative
NextCure Inc (NXTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NextCure Inc (NXTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NextCure Inc (NXTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NextCure Inc. (NXTC) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Zero Revenue Weighs on Shares - newsline.com
NXTC Q1 2026 Earnings: Narrower Loss Beats Estimates, No Revenue YetEarnings Decline Risk - newsline.com
Experimental drug shrinks tumors in hard-to-treat cancers - Rare Cancer News
NextCure Inc stock (US65343E1082): Pipeline focus after restructuring and cash runway update - AD HOC NEWS
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - The Manila Times
Cancer experts discuss SIM0505 trial data in on-demand replay - Stock Titan
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Driven by Lower Operating Costs, Stock Falls on Cash Runway ConcernsRevenue Warning Signal - newsline.com
What's Going On With NextCure Stock Wednesday? - Benzinga
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous CarcinomaSlideshow (NASDAQ:NXTC) 2026-06-02 - Seeking Alpha
Lucid Capital Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
NextCure Reports 55% Response Rate in Phase 1 SIM0505 Trial for Gynecologic Cancers at ASCO 2026 - Minichart
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data - TipRanks
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - The Manila Times
NextCure presents SIM0505 Phase 1 data: 55% ORR in gynecologic cancers; cash runway into Q1 2027 - TradingView
NextCure reports 55% response rate for SIM0505 in gynecologic cancers - Investing.com
Strong SIM0505 Phase 1 gynecologic cancer data for NextCure (Nasdaq: NXTC) - Stock Titan
Experimental ovarian and uterine cancer drug shows 55% response rate - Stock Titan
NXTC Q1 2026 Earnings: Narrower-Than-Expected Loss Driven by Cost DisciplineProfitability Analysis - The Legal Advocate
NextCure Inc. (NXTC) Surges 5.44% as Shares Test Key ResistanceGap Up Stocks - The Legal Advocate
NXTC - Finviz
NXTC Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock GainsEarnings Yield Spread - newsline.com
NextCure (NXTC) Plunges Over 22% as Selling Pressure IntensifiesWedge Breakout - The Legal Advocate
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Amid No Revenue and Steep Stock DeclineEarnings Sentiment Score - The Legal Advocate
NextCure Inc. (NXTC) Gains 5.75% as Biotech Stock Tests Resistance Near $10.71Bollinger Band - Newser
NextCure stock (US65343E1082): biotech shares in focus after China licensing deal for SIM0505 - AD HOC NEWS
Finanzdaten der Nextcure Inc-Aktie (NXTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):